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Introduction
Loss of  functional small bowel surface area following surgical resection for Crohn’s disease, ischemic inju-
ry, radiation enteritis, trauma, or malignancy may result in short bowel syndrome (SBS), an important 
cause of  morbidity, mortality, and health care costs in the United States (1). Necrotizing enterocolitis and 
congenital disorders such as atresia and gastroschisis are the major causes of  SBS in children. Following 
resection, the remaining small bowel epithelium mounts an adaptive response, resulting in increased crypt 
cell proliferation, increased villus height, increased crypt depth, and enhanced nutrient and electrolyte 
absorption (2). The functional and morphometric adaptive response is best described in animal models. In 
humans, this response is influenced by remnant small bowel length, the presence or absence of  a colon, and 
underlying disease activity, yet even accounting for these factors, the response may be unpredictable and 
inadequate (1, 3). Even with an accurate assessment of  remnant small bowel length, it may require from 2 
to 5 years to determine which patients will wean off  parenteral (intravenous) nutrition (4).
There are few studies of  gut adaptation in human SBS, and these are inconclusive because of  limited 
numbers of  patients (5, 6). Patients with SBS have been reported to have an increase (7, 8) or no change (9–11) 
in crypt cell proliferation rates and morphologic adaptation after resection (reviewed in ref. 6). These studies, 
which are clinically heterogeneous, include studies of  infants (7), jejunoileal bypass patients (8), and colon 
adaptation (9). Only 2 studies have focused on the small bowel (10, 11). These report modest numbers of  
patients (11) with limited data on crypt-villus morphometrics (10) and no analysis of  stem cell and crypt pro-
liferative responses. Furthermore, treatments for SBS are for the most part nonspecific and are directed toward 
symptomatic diarrhea control. Only one therapy has been developed that is specific to SBS, teduglutide. This 
glucagon-like peptide 2 analog has multiple proadaptive effects, including increasing crypt cell proliferation, 
crypt depth, and villus height. Teduglutide is effective in reducing parenteral nutrition (PN) requirements in 
Loss of functional small bowel surface area following surgical resection for disorders such 
as Crohn’s disease, intestinal ischemic injury, radiation enteritis, and in children, necrotizing 
enterocolitis, atresia, and gastroschisis, may result in short bowel syndrome, with attendant high 
morbidity, mortality, and health care costs in the United States. Following resection, the remaining 
small bowel epithelium mounts an adaptive response, resulting in increased crypt cell proliferation, 
increased villus height, increased crypt depth, and enhanced nutrient and electrolyte absorption. 
Although these morphologic and functional changes are well described in animal models, the 
adaptive response in humans is less well understood. Clinically the response is unpredictable and 
often inadequate. Here we address the hypotheses that human intestinal stem cell populations 
are expanded and that the stem cell niche is regulated following massive gut resection in short 
bowel syndrome (SBS). We use intestinal enteroid cultures from patients with SBS to show that the 
magnitude and phenotype of the adaptive stem cell response are both regulated by stromal niche 
cells, including intestinal subepithelial myofibroblasts, which are activated by intestinal resection 
to enhance epithelial stem and proliferative cell responses. Our data suggest that myofibroblast 
regulation of bone morphogenetic protein signaling pathways plays a role in the gut adaptive 
response after resection.
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properly selected patients, of  whom a subset may completely wean from PN. Yet others remain at least par-
tially PN dependent, are ineligible for this medication, or develop side effects (12). Thus additional therapies 
are needed. Critical interactions between luminal and host signaling pathways that modulate the stem cell/
proliferative and functional adaptive response have yet to be elucidated. Accordingly, understanding the sig-
naling pathways that modulate intestinal stem cell interactions with the local (niche) environment following 
small bowel resection is a critical unmet need.
Mesenchymal cells play an important role in the gut stem cell niche, in health and in injury and disease 
(13, 14). We and others have shown that intestinal subepithelial myofibroblasts (ISEMFs) have stem cell 
niche activity in mouse gut and support stem cell survival and growth of  cocultured epithelial stem cell–
derived enteroids (15–17). Our previous studies suggest an important role for epimorphin, a syntaxin that 
regulates growth factor and cytokine secretion from ISEMFs (15–17). Also cell populations in mice marked 
by FOXL1 (18, 19), PDGFRα (20), Gremlin1 (21), GLI1 (22, 23), and CD34/GP38 (24) have significant 
niche activity and are required for stem cell proliferation. Single-cell RNA-Seq analysis of  colon biop-
sies from patients with ulcerative colitis has revealed novel mesenchymal populations with stem cell niche 
activity that may serve as targets for therapy (13). However, the characterization and role of  these stromal 
populations in human gut and in SBS are unknown.
Here we address the hypotheses that a subset of  intestinal stem cells are expanded and that the stem 
cell niche is regulated following massive gut resection in human SBS. The magnitude and phenotype of  
the adaptive stem cell response is regulated by stromal niche cells, including ISEMFs that are activated 
by intestinal resection to enhance epithelial stem and proliferative cell responses. Our data suggest that 
ISEMF regulation of  bone morphogenetic protein signaling pathways plays a role in the gut adaptive 
response following small bowel resection.
Results
Human SBS stem cell isolation. To examine the effects of  massive small bowel resection and resulting 
SBS on small intestinal stem cell populations and the stem cell niche in humans, we collected small 
bowel biopsies from 17 patients with SBS and from 24 control subjects, obtained as part of  routine 
clinical care (see Methods). The demographics of  the SBS population, including age, sex, race, etiol-
ogy of  SBS, and diet history (oral vs. parenteral nutrition) are summarized in Table 1, and details are 
reported in Supplemental Table 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.137905DS1. SBS patients included those fed an oral diet only or fed partially or 
completely with PN for various times postresection. There were 9 patients with more than 50% colon 
remaining in continuity, 1 patient with a sigmoid colostomy who had less than 50% colon remaining, 
and 7 patients with small bowel ostomies. SBS resulted from Crohn’s disease (n = 6), radiation enteritis 
(n = 3), ischemia (n = 4), fistula (n = 1), trauma (n = 1), and adhesions (n = 2). There were 7 men and 
10 women, with an average age of  59.6 years; 6 patients were fed with oral nutrition only.
Transit amplifying cells and leucine rich repeat containing G protein-coupled receptor 5–positive intestinal 
stem cells are increased in patients with SBS. Total RNA was isolated from small bowel biopsies, and 
expression of  transit amplifying proliferative crypt cell gene markers (KI67 and CD44) and stem cell 
gene markers (leucine rich repeat containing G protein-coupled receptor 5 [LGR5], SRY-box transcrip-
tion factor 9 [SOX9], and BMI1 proto-oncogene, polycomb ring finger [BMI1]) was analyzed by quan-
titative reverse transcription PCR (qRT-PCR).
Expression of  KI67 and CD44 mRNA was significantly increased in SBS compared with normal 
patient biopsies (Figure 1A), consistent with increased crypt transit amplifying cell proliferation (a 
hallmark of  mouse models of  adaptation following resection; refs. 25, 26). EGFR/RAS/MAPK sig-
naling is a major driver of  proliferation that promotes the exit of  stem cells into the transit amplifying 
cell population (27). Therefore we measured EGFR mRNA expression by qRT-PCR and observed 
a significant increase in EGFR expression in SBS (Figure 1A). To correlate mRNA with cell-specif-
ic expression, we analyzed KI67 expression by immunohistochemical analysis (Figure 1, B–E). SBS 
biopsies showed lengthening of  the crypts compared with normal biopsies, and immunohistochemis-
try showed increased crypt expression in the transit amplifying population associated with increased 
crypt depth in patients with SBS (Figure 1, B–E).
To determine whether the increase in transit amplifying cell proliferation also reflected an expansion of  
stem cell populations, we examined expression of  LGR5, the definitive marker of  the rapidly dividing gut 
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crypt base stem cell population that replenishes epithelial cells lost by daily cell turnover (Figure 1F). We 
observed a significant increase in LGR5 expression in SBS biopsies compared with normal patients.
In contrast, expression of the quiescent +4 stem cell population marker, SOX9 (28), was unchanged in SBS, 
and expression of BMI1, a putative marker of the quiescent +4 stem cell population and of enteroendocrine 
cells that dedifferentiate when injured to become stem cells (29), was not significantly increased (Figure 1F).
We next examined cell-specific LGR5 expression in SBS biopsies by in situ hybridization analysis using 
RNAscope fluorescence assays. As expected, LGR5 mRNA was located at the base of  the crypts (Fig-
ure 2A). Quantitation of  cellular LGR5 mRNA expression by ImageJ (NIH) analysis showed significantly 
increased expression in SBS (Figure 2B; P = 0.034).
Increased stem cell activity in human SBS. To determine whether the increase in LGR5 expression was 
reflected by a functional increase in stem cell activity, we performed stem cell–initiated enteroid formation 
assays and compared the ability of  SBS compared with normal patient stem cells to form enteroids (Figure 
3). Crypts were isolated from SBS and normal intestinal biopsies, dissociated, and cultured to produce stem 
cell–derived enteroids. These were passaged twice, released from Matrigel, and frozen. To perform stem 
cell enteroid initiation assays, stem cells from SBS (n = 7) and healthy patients (n = 12) were obtained from 
frozen stem cell stocks. Single stem cells were plated in Matrigel, and the number of  surviving enteroids 
was imaged and counted on day 7 after plating.
Patients with SBS had a significant increase in the number of  stem cell–derived enteroids compared 
with healthy subjects (Figure 3, A and C), providing a functional correlation for the observation that 
LGR5 mRNA levels were increased in SBS (Figure 1 and Figure 2). These results also indicate that 
even after passaging and freezing, SBS stem cells retained the observed in vivo phenotype for expansion 
compared with normal stem cells. Enteroid size (cross-sectional area), which reflects growth of  each 
surviving stem cell–derived colony, was unchanged in SBS compared with normal subjects (Figure 3B).
WNT ligand and target gene expression in SBS. LGR5+ stem cell proliferation and commitment to specific 
differentiation pathways are regulated by WNT, BMP, and NOTCH signaling (30), contributing to auto-
crine and niche regulation of  stem cell maintenance and expansion. To begin to assess WNT signaling 
activity in SBS, we examined expression of  downstream WNT target genes including AXIN2, cyclin D1, 
and C-MYC; WNT signaling pathway components including dickkopf  WNT signaling pathway inhibitor 1 
(DKK1) and β-CATENIN; and WNT agonists and ligands by qRT-PCR. Although LGR5+ cell populations 
were expanded, there was no change in WNT target gene expression, including cyclin D1, C-MYC, DKK1, or 
β-CATENIN, and AXIN2 expression showed a trend to be decreased in SBS compared with normal biopsies 
Table 1. Demographic data for SBS patients
Number of patients 17





 Radiation enteritis 3






 On TPN 11
 Off TPN 6
Colon/No colon
 Remnant colon (>50%) in continuity 9
 Remnant colon (<50%) in continuity 1
 Small bowel ostomy 7
TPN, total parenteral nutrition.
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(Figure 4A, P = 0.054). In contrast, expression of  LGR4–6 receptor ligands/WNT agonists R-spondin1 and 
R-spondin2 was significantly increased in SBS versus normal biopsies (Figure 4B). R-spondin3 expression 
was unchanged. R-spondin1 is expressed in epithelial and mesenchymal cells; R-spondin2 and R-spondin3 
are expressed predominantly in mesenchyme (31, 32). The mRNA expression of  the mesenchymal WNT 
ligand WNT5a was also increased.
BMP signaling pathways are regulated in human SBS. Increased ligand expression without concomitant 
increased WNT signaling activity suggested that the SBS mesenchyme generates a stromal niche adaptive 
response following resection to facilitate stem cell expansion, but WNT signaling activity may be inhibited 
Figure 1. Increased crypt cell proliferation in small bowel biopsies from SBS patients compared with normal con-
trol subjects. (A) Increased KI67 (*P = 0.027), CD44 (*P = 0.012), and EGFR (*P = 0.011) mRNA levels in SBS versus 
normal small bowel, quantified by qRT-PCR. (B–E). Representative images of immunohistochemical analysis of KI67 
expression (brown cells) in normal (B and C) and SBS (D and E) small bowel. Arrows depict representative full-length 
intestinal crypts. Scale bars: 100 μm (B and D), 50 μm (C and E). (F) Increased LGR5 mRNA levels (**P = 0.007) in 
SBS versus control small bowel. The mRNA levels of +4 position stem cell markers SOX9 and BMI1 are unchanged. 
SBS: n = 9–12; normal: n = 16–24. Data are means ± SEM. Statistical analysis by Student’s t test.
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by other counterregulatory pathways such as the BMP pathway. BMP signaling plays a role in the small 
intestinal stem cell niche, regulating crypt cell proliferation and epithelial cell differentiation (30). BMP 
signaling activity is lowest at the base of  the crypt, due to enriched mesenchymal expression of  BMP inhib-
itors including noggin, gremlin, and chordin (33, 34), and increases along the crypt/villus axis as cells exit 
the crypt and differentiate during migration onto the villus, inhibiting stem and crypt cell proliferation and 
promoting epithelial cell differentiation.
We quantified mRNA expression of  BMP4, BMP2, and BMP7 and BMP inhibitors noggin, gremlin1, chor-
din, and follistatin. Expression of  BMP4 mRNA, which inhibits stem and crypt cell proliferation and pro-
motes epithelial differentiation, was significantly increased in SBS intestine (Figure 5A). BMP2 and BMP7 
showed no change (data not shown). Conversely expression of  BMP inhibitors gremlin1, noggin, chordin, and 
follistatin were unchanged in SBS versus controls.
To further examine whether BMP signaling activity is regulated in SBS, we next examined expression of  
phosphorylated SMAD1,5,8 (p-SMAD1,5,8), the major downstream target of  BMP signaling by immuno-
blot. We found that SBS biopsies had increased p-SMAD1,5,8 expression compared with normal gut, which 
showed low basal levels of  p-SMAD1,5,8 expression (Figure 5B, Supplemental Figure 1). Thus BMP signal-
ing activity appears to be increased overall in SBS mucosa.
Mesenchymal stem cell niche populations in SBS. To further explore the cellular basis for the increase 
in mesenchymal WNT ligand, WNT agonist (R-spondins), and BMP4 expression, we examined the 
adaptive SBS response of  gut mesenchymal (stromal) cell populations that have stem cell niche activity 
(13, 18–20, 22, 24, 27) by cell marker expression analyses using qRT-PCR. Gut mesenchymal popula-
tions include ISEMFs, which are smooth muscle α-ACTIN–positive (SMA-positive), vimentin-positive, 
and desmin-negative cells that express epimorphin, a myofibroblast protein that regulates growth factor 
secretion (15, 16); and FOXL1+ telocytes, which also have been shown to play a role in the stem cell 
niche in mouse models and in human inflammatory bowel disease (13). Also CD34+/GP38+ cells (24) 
and SMA–/ PDGFRα+/R-spondin3+ cells have been described in mouse intestine (20). These cells all 
express PDGFRα (27) and are the source of  WNT ligands and R-spondins, including WNT2b, WNT4, 
and WNT5a; R-spondin1, 2, and 3; and BMPs (27).
Expression of  vimentin, SMA, and epimorphin mRNA was significantly increased in SBS biopsies by 
qRT-PCR (Figure 6A) consistent with expansion and/or activation of  myofibroblasts, which express 
mesenchymal WNTs and R-spondin1, 2, and 3. In addition, FOXL1 and PDGFRα mRNA expression 
was increased in SBS versus control small bowel (Figure 6); in contrast, CD34 expression was reduced 
and expression of  GP38 and Rspondin-3 (as per Figure 4B) was unchanged. Therefore, subpopulations 
of  some, but not all, PDGFRα+ cells respond to loss of  functional small bowel surface area, suggesting 
cell-specific adaptation.
Figure 2. LGR5 mRNA expression is increased in the crypt base of SBS compared with control ileum. (A) In situ hybridization by RNAscope to detect LGR5 
mRNA (small green dots, white arrows) on sections of normal ileum (top panels) and SBS ileum (bottom panels). Slides are counterstained with DAPI for 
nuclei (blue). Orange arrows denote lamina propria cells that have intrinsic autofluorescence leading to artifact. (B) Quantitation of the number of LGR5+ 
dots per crypt from sections of normal (n = 8) and SBS (n = 6) ileal biopsies (*P = 0.034). Data are means ±  SEM. Statistical analysis by Student’s t test.
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To examine the cellular basis for the increased expression of  multiple mesenchymal cell markers, we 
performed immunohistochemical analysis to detect PDGFRα+ cells. We noted a significant increase in 
PDGFRα+ cells in the villus cores of  SBS compared with control biopsies (Figure 6, B and C).
Outlier and subgroup analyses. Outlier analyses followed by additional subgroup analyses were per-
formed for all the data reported in Figure 1, Figure 4, Figure 5, and Figure 6 to determine whether 
outliers have a unique clinical phenotype, as per Methods. We found no association of  outliers with 
the presence or absence of  a colon in continuity, age, sex, intestinal location (duodenum, jejunum, or 
ileum), or oral feeding versus PN.
SBS ISEMFs increase growth of  cocultured SBS enteroids. To further explore mesenchymal cell–specific 
effects on stem cell proliferation and the stem cell niche, we isolated human ISEMFs from SBS and normal 
control patient biopsies. ISEMFs were chosen for further study because these cells expressed activation 
markers in SBS compared with normal intestine, (α-SMA; Figure 6). ISEMFs were cocultured with SBS 
and normal stem cells, and the number and size (surface area) of  surviving enteroids were measured after 7 
days in coculture (Figure 7). We found that SBS enteroid size increased when cocultured with SBS ISEMFs 
compared with cocultures with normal patient ISEMFs (Figure 7, A and C). In contrast, there was no effect 
on the size of  normal enteroids when cocultured with SBS compared with normal ISEMFs, suggesting a 
specific interaction between SBS ISEMFs with SBS enteroids.
The number of  stem cell–derived enteroids was significantly lower in normal enteroid–SBS ISEMF 
cocultures compared with normal enteroid–normal ISEMF cocultures (Figure 7B). In contrast, there was 
no change in SBS enteroid cell count when cocultured with normal versus SBS ISEMFs, again suggesting 
that SBS enteroids have cell-autonomous changes that alter their response to coculture with ISEMFs.
To elucidate the mechanisms underlying the effect of  SBS ISEMFs on SBS enteroid growth, we 
examined markers of  myofibroblast activation and function in isolated ISEMFs (Figure 8, A and B). 
SBS ISEMFs exhibited increased SMA mRNA expression compared with normal ISEMFs. In contrast, 
epimorphin mRNA expression was decreased in SBS compared with normal patient ISEMFs, consistent 
with observations in mouse intestinal adaptation after resection (35) and with studies which showed that 
Figure 3. Stem cell expansion in small intestine from patients with SBS. Stem cells isolated from small bowel biopsies from 
patients with SBS and from normal controls were plated for stem cell enteroid initiation assays as per Methods. The number 
of enteroids per well and enteroid size (cross-sectional area) were quantified using the Cytation 3 plate reader. (A) Average 
number of stem cell–derived enteroids from biopsies from normal patients (n = 12) and SBS patients (n = 7) that were grown 
in Matrigel for 7 days. *P = 0.0178. Twenty wells were analyzed for each patient, and experiments were repeated at least twice. 
(B) Average cross-sectional area of SBS (n = 7) versus normal (n = 12) patient stem cell–derived enteroids. All data are means 
± SEM. Statistical analysis by Student’s t test. (C) Photomicrographs of normal (left panel) and SBS (right panel) stem cell–
derived enteroids. Scale bar: 50 μm, imaged by Zeiss Axiophot with Apotome 2 microscopy.
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epimorphin deletion in mouse gut results in enhanced crypt cell proliferation (36) and increased enteroid 
growth in Epim–/– ISEMF-enteroid cocultures (15). Expression of  other mesenchymal markers such as 
FOXL1 and PDGFRα was unchanged in SBS versus normal ISEMFs.
BMPs are expressed and secreted by ISEMFs; therefore we examined SBS and normal myofibroblast 
expression of  members of  the BMP signaling pathway, including BMP4 and inhibitors chordin and noggin. 
In contrast to what we observed in SBS biopsies, which reflects an average increase in BMP4 expression 
across all cell types (Figure 5), we observed a significant decrease in BMP4 mRNA expression in SBS 
ISEMFs compared with controls (Figure 8C), without change in noggin or chordin mRNA expression, sug-
gesting ISEMF cell-specific regulation of  BMP expression.
To determine if  reduced BMP4 expression in and secretion from SBS ISEMFs could explain the 
growth-inducing effect of  these cells on SBS enteroids, we cocultured SBS enteroids with SBS ISEMFs, 
Figure 4. WNT signaling pathway component gene expression in SBS versus control small intestinal biopsies. Relative 
mRNA levels were measured by qRT-PCR. (A) WNT target gene analysis shows that AXIN2 mRNA expression showed 
a trend to be decreased in SBS versus control ileum, P = 0.054, but other target gene mRNA levels are unchanged. (B) 
WNT5A and R-SPONDIN1 and 2 mRNA levels are increased in SBS. Normal: n = 13–24; SBS: n = 7–12. WNT5A *P = 0.049; 
R-SPONDIN1 *P = 0.048; R-SPONDIN2 **P = 0.01. Data are means ± SEM. Statistical analysis is by Student’s t test.
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without the BMP inhibitor noggin and with recombinant BMP4 (25 ng/mL; Figure 9) or vehicle. Addition 
of  BMP4 reversed the SBS ISEMF-induced increase in enteroid size (Figure 9A) but had no effect on the 
size of  normal enteroids when cocultured with normal or SBS ISEMFs (Figure 9B). Thus it appears that 
BMP signaling is inhibited in SBS ISEMF–SBS enteroid cocultures, resulting in increased growth. In con-
trast, the reduction in the number of  stem cell–derived normal enteroids when cocultured with SBS versus 
normal ISEMFs (Figure 7B) was not reversed by addition of  BMP4 (Figure 9C). Thus reduced BMP sig-
naling resulted in an increase in SBS but not normal enteroid growth, but this signaling pathway does not 
direct the reduction in enteroid number, suggesting regulation of  this response by other factors/pathways.
Discussion
Here we report that massive intestinal resection regulates stem and stromal niche cell populations in the 
residual gut in humans with SBS. We have analyzed small bowel biopsies as well as in vitro enteroid and 
stromal ISEMF cell culture models to begin to elucidate underlying mechanisms for the human adaptive 
response and to identify potential novel targets for therapy. Our study is unique in that we have obtained 
mucosal small bowel biopsies from a large cohort of  patients with SBS, a critically important step forward 
because this is a clinically heterogeneous population (37). Prior studies (5, 7–11) of  the cellular and mor-
phometric features of  the human gut adaptive response have been limited by small sample size.
We found that the adaptive SBS intestine has an expanded stem cell population, as shown by stem cell–
initiated enteroid formation assays (Figure 3) and by increased expression of  LGR5 mRNA (Figure 1 and 
Figure 2), the intestinal stem cell marker of  the rapidly cycling crypt base stem cell that is responsible for dai-
ly renewal of  the small bowel epithelium (38). Our analysis of  the SBS mesenchyme shows a selective expan-
sion of  a subset of  stromal cells with putative roles in regulating the stem cell niche. Our data indicate that 
there is a specific stromal cell adaptive response rather than just a general increase in all stromal cells because 
we showed that cells expressing CD34/GP38 (Figure 6), which have niche activity in mice (22, 24), were 
not expanded in intestinal biopsies from human subjects with SBS. We further show that ISEMFs induce 
growth of  cocultured stem cell–initiated enteroids via reduced BMP signaling but only in the setting of  SBS.
We found that slower cycling “reserve” +4 stem cell populations marked by SOX9 (28) and BMI1 (39) 
are not expanded in SBS intestine, findings that contrast with the expansion of  LGR5+ cells. The biopsies 
collected in this study were from patients who had SBS for a duration of  6 months up to more than 10 
years. It is possible that the reserve stem cell population responds to resection at earlier times after surgery, 
Figure 5. BMP signaling pathway mRNA expression in SBS versus normal small bowel biopsies. (A) Total RNA was isolated from normal (n = 12–23) and SBS 
(n = 6–10) small bowel biopsies, and mRNA levels were quantified by qRT-PCR. BMP4 **P = 0.009; data are means ± SEM. Statistical analysis by Student’s 
t test. (B) Immunoblot to detect p-SMAD1,5,8 expression in SBS compared with normal ileum. First lane (left), molecular weight markers; second and third 
lanes, SBS; n = 2 patients pooled per lane); and fourth lane, normal (n = 2 patients pooled). (C) Quantitation of relative p-SMAD1,5,8 protein expression 
was performed by optical densitometric (LI-COR) analysis of p-SMAD1,5,8 and β-actin bands. p-SMAD1,5,8 expression was normalized to β-actin, and SBS 
p-SMAD1,5,8 expression was calculated relative to normal ileal expression.
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e.g., in the first few months postresection. These biopsies are more difficult to obtain given the severity 
of  illness early after resection but are required to specify which stem cell population(s) are first mobilized 
following extensive resection.
Although LGR5 mRNA expression was significantly increased in small bowel biopsies from SBS versus 
control patients and stem cell–initiated enteroid formation was greater in SBS patients compared with con-
trols (Figure 1, Figure 2, and Figure 3), we observed patient-to-patient variability for all the analyses. Due to 
the limited number of  samples, we were unable to subdivide our groups to analyze adaptive gene expression 
in biopsies from patients who had a colon in continuity versus those with ileostomy or jejunostomy, from 
patients who were on oral versus parenteral feeding, and so on. We also pooled duodenal, jejunal, and ileal 
biopsies from SBS patients and normal subjects, while recognizing that geographic differentiation could 
affect the results. However, we focused on analyzing expression of  genes that have similar, general functions 
throughout the gastrointestinal (GI) tract (proliferation, stem cell function, etc.). Also, we performed outlier 
analyses of  all the biopsy-derived mRNA expression data, followed by additional subgroup analysis to see 
if  the outliers had a unique clinical phenotype. Outlier analysis did not reveal a correlation with age, sex, 
Figure 6. Mesenchymal cell marker gene expression analyses. Stem cell niche mesenchymal cell marker gene expression by qRT-PCR analysis of mRNA 
from normal (n = 12–24) and SBS (n = 9–13) small bowel biopsies. (A) A subset of mesenchymal markers including myofibroblast markers (epimorphin, 
αSMA, vimentin) and PDGFRα and FOXL1 exhibited increased mRNA levels in SBS versus normal small bowel. Epimorphin *P = 0.042; αSMA *P = 0.024; 
vimentin **P = 0.012; FOXL1 *P = 0.049; PDGFRα *P = 0.009; CD34 *P = 0.025. Data are means ± SEM. Statistical analysis by Student’s t test. (B) PDGFRα+ 
cells (brown stained cells) in normal (upper panel) and SBS (lower panel) ileal biopsies detected by immunohistochemical analysis, using a mouse anti-hu-
man PDGFRα antibody. Black arrows on high-power views (right panels) show PDGFRα+ cells subjacent to the villi. Red arrows on low-power view (left pan-
els) depict the crypts. Green arrows (middle panels) show the crypt-villus junction. Scale bars: 100 μm (left), 50 μm (middle), 20 μm (right). (C) The number 
of crypt- and villus-associated PDGFRα+ cells was quantified in SBS patient crypts (n = 8) and villi (n = 9) and normal patient crypts (n = 11) and villi (n = 11). 
Each data point represents the average percentage of positive cells per patient. Only intact villi and crypts on each histologic section were analyzed. *P = 
0.031. Data are means ± SEM. Statistical analysis by Student’s t test.
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presence or absence of  colon, location of  biopsy (duodenum, jejunum, or ileum), or oral versus parenteral 
feeding (i.e., on vs. off  TPN). This variability also did not appear to result from differences in the size or 
mucosal/submucosal depth of  the biopsies because there was no consistent pattern of  very high or very low 
expression levels of  multiple genes in an individual patient. Similarly, increased expression of  epithelial and 
stromal marker genes in SBS was not simply due to adaptive crypt and villus hyperplasia because multi-
ple markers of  the proliferative, differentiating, and stromal epithelium showed no difference in expression 
levels in SBS versus normal gut (e.g., SOX9, GP38, gremlin, β-CATENIN). However, firm conclusions about 
whether there is a significant association with specific demographic features or with disease process (e.g., 
Crohn’s disease, ischemia, adhesions) will require analysis of  larger numbers of  samples per group.
SBS-induced stem cell expansion and increased stem cell function measured by assays of  stem cell–
derived enteroid initiation (Figure 3) were preserved in these cells following several passages and in assays 
which used stem cells that had been passaged and were frozen for storage. This phenotypic preservation with 
passaging and after removal of  both luminal and submucosal signals suggests a cell-autonomous mechanism, 
and specifically, epigenetic modulation has been shown to be responsible for preservation of  other phenotypic 
changes. For example, others have shown that regional small bowel epithelial identity along the horizontal 
axis (e.g., from duodenum to ileum) is recapitulated in enteroids due to preservation of  intrinsic DNA meth-
ylation patterns with passaging and in long-term culture (40). DNA methylation profiles were preserved inde-
pendent of  the cellular environment in adult and pediatric organoids, but interestingly fetal organoids showed 
Figure 7. SBS ISEMFs increase surface area of cocultured ileal SBS enteroids. Normal enteroids (n = 9 patients) and 
SBS enteroids (n = 6 patients) were cocultured for 7 days with normal (n = 4 subjects) or SBS (n = 4 patients) ISEMFs. 
Enteroid cross-sectional area (A) and the number of enteroids (cell count, B) were quantified by Cytation 3. (A) SBS 
enteroid size ***P = 0.0006; (B) Normal enteroid cell count **P = 0.0068; SBS enteroids = cell count, NS. Data are 
means ± SEM. Statistical analysis by Student’s t test. (C) Images of ISEMF-enteroid cocultures by Zeiss Axiophot 
microscope with Apotome 2 attachment. Scale bar: 50 μm.
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in vitro maturation, with changes in DNA methylation in culture. Also, disease-specific changes in methyla-
tion were identified in organoids derived from a patient with gastric heterotopia, which were also preserved 
in passaging. Similarly, changes in Crohn’s disease and ulcerative colitis patient enteroid gene expression 
patterns compared with normal enteroids are also preserved after passaging, likely due to retained epigenetic 
changes (41, 42). Similar epigenetic mechanisms are likely to be operative in the setting of  SBS.
BMP signaling activity is regulated along the crypt/villus axis. BMP inhibitors are produced by 
pericryptal stromal cells in humans (33). Inhibition of  BMP signaling activity is highest at the crypt 
base where WNT signaling activity is highest, promoting stem cell expansion. BMP4 is expressed in 
mesenchymal cells adjacent to intestinal stem cells, and noggin is expressed in submucosal cells adja-
cent to the crypt bottom in mice (43). Stem cell dependence on BMP inhibition is well established, as 
illustrated by the requirement for exogenous noggin for successful growth of  stem cell–derived enteroid 
cultures in vitro (44). BMP signaling activity increases above the crypt base, from the midcrypt and 
higher along the crypt/villus axis, to inhibit crypt cell proliferation in the transit amplifying zone and 
promote epithelial differentiation, counterbalancing WNT signaling activity (30, 45). Mesenchymal 
BMP expression and BMP signaling activity increase from midcrypt onto the villus (30, 45). BMPs 
are expressed by mesenchymal cells including ISEMFs (Figure 8 and refs. 16, 34) and Foxl1+ telocytes 
Figure 8. Mesenchymal marker and BMP signaling pathway gene expression in normal and SBS ISEMFs. (A) SBS ISEMFs have increased α-SMA (*P = 0.0109) 
but reduced epimorphin mRNA expression (*P = 0.0264) compared with normal ISEMFs. Data are mean ± SEM. Statistical analysis by Student’s t test. There 
was no change in FOXL1 or PDGFRα mRNA expression. (B) Immunohistochemical analysis of human normal and SBS ISEMFs shows expression of myofibro-
blast marker genes α-SMA and vimentin. (C) BMP4 signaling pathway gene expression in SBS ISEMFs. ISEMFs from normal and SBS patient biopsies were iso-
lated as per Methods. BMP4 mRNA is reduced in SBS. *P = 0.0528. SBS, n = 4; normal, n = 7–8. Data are means ± SEM. Statistical analysis by Student’s t test.
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(in mice) (19) and by stromal cells in human colon (BMPs 2, 5, and 7) that have yet to be fully char-
acterized (13). The major small intestinal BMPs are BMP2, BMP4, and BMP7 (45). In mice, BMP4 
and BMP inhibitors are expressed by mesenchymal cells whereas BMP2 is expressed by the epithelium 
(33). In humans, single-cell RNA-Seq shows that BMP2 and BMP5 are expressed in a unique subset of  
colon stromal cells (13); BMP2 and 4 are expressed in human small bowel in epithelium and in stroma, 
respectively (The Human Protein Atlas, https://www.proteinatlas.org/search/bone+morphogenet-
ic+protein), but cell-specific expression patterns of  other BMPS and inhibitors in human small intestine 
have not yet been elucidated.
Our analysis of  SBS versus normal patient biopsies shows an increase in BMP4 mRNA and increased 
p-SMAD1,5,8, consistent with increased BMP4 signaling overall, which is active on the villus and is 
required for epithelial differentiation. Yet, our analysis of  crypt-derived enteroid-specific interactions with 
ISEMFs suggests a local, crypt-specific decrease in BMP signaling (Figure 8 and Figure 9). This is consis-
tent with BMP signaling inhibition at the crypt base. We observed that ISEMFs from SBS patients have 
reduced BMP4 mRNA expression compared with normal ISEMFs (Figure 8), and incubation of  ISEMF-
SBS enteroid cocultures with exogenous BMP4 reverses the SBS ISEMF-induced increase in enteroid sur-
face area (Figure 9). Thus the SBS ISEMF stromal cell population responds to resection locally at the crypt, 
by inhibiting BMP expression, favoring increased crypt cell proliferation.
Cocultures of  SBS ISEMFs versus normal ISEMFs with SBS stem cell–derived enteroids induced 
growth (increased surface area) of  cocultured enteroids but not stem cell expansion; the number of  
stem cell–initiated enteroids in SBS-ISEMF-SBS enteroid cocultures compared with normal ISEMF-
SBS enteroid cocultures was not significantly decreased (Figure 7). Also, comparison of  normal 
Figure 9. BMP4 reverses the effects of SBS ISEMFs on cocultured SBS enteroid growth. (A) SBS enteroids were cocultured with normal human ISEMFs 
or with SBS ISEMFs in enteroid growth conditioned media (CM), in CM without noggin (-noggin), or in CM without noggin but with BMP4 (BMP4 25 ng/
mL, BMP4 -noggin). BMP4 reversed the increase in enteroid size induced by coculture with SBS ISEMFs. **P = 0.0064; *P = 0.04. (B) Normal enteroids 
were cocultured with normal or SBS ISEMFs in CM, in CM without noggin, or in CM without noggin but with BMP4. No change in enteroid size was noted. 
(C) Normal enteroids were cocultured with normal ISEMFs without noggin, with normal ISEMFs without noggin but with BMP4, with SBS ISEMFs with-
out noggin or with SBS ISEMFs without noggin plus BMP4, and cell count was measured. A significant decrease in enteroid cell count was observed in 
cocultures with SBS ISEMFs. *P = 0.01 normal enteroids with normal ISEMFs versus normal enteroids with SBS ISEMFs; with BMP4; this decrease was 
not reversed by treatment with BMP4. SBS enteroids, n = 4 patients; normal enteroids, n = 5–7 patients; normal ISEMFs, n = 3 patients; SBS ISEMFs, n = 4 
patients. Data are mean ± SEM. Statistical analysis by Student’s t test.
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enteroid–SBS ISEMF cocultures with normal enteroid–normal ISEMF cocultures revealed a signif-
icant decrease in the number of  stem cell–initiated enteroids but no change in surface area/growth. 
These results suggest that SBS ISEMFs expand the proliferative transit amplifying cell program, result-
ing in increased enteroid growth in coculture, but do not have direct effects on the stem cell popula-
tion. Thus, other stromal cell populations (e.g., FOXL1 telocytes, other PDGFRα+ cells; refs. 13, 19, 
20, 27) or stem cell/epithelial autonomous mechanisms may regulate the observed expansion in SBS 
(Figure 3). The observation that coculture of  SBS ISEMFs increases growth of  SBS stem cell–derived 
enteroids but not normal enteroids (Figure 7 and Figure 9) suggests resection-induced changes in cell 
surface growth factor or growth inhibitor receptor expression that are specific to SBS enteroids. Fur-
ther studies are required to elucidate these mechanisms.
The role of  WNT signaling activity in establishing and maintaining stem cell expansion and amplifying 
population crypt cell proliferation in the human adaptive intestine has not been previously studied to our 
knowledge. Limited experiments in rodent adaptation following resection show that Apcmin/+ mice have an 
increased crypt cell proliferative response early after resection (e.g., 72 hours after resection; ref. 46), yet 
Wnt signaling does not play a role in maintaining this morphometric response (47). Others have shown 
that Wnt signaling is inactive in the mouse gut transit amplifying cell population, although EGFR/RAS/
MAPK signaling enhances proliferation of  this cell population (27, 48). We found that EGFR expression 
was significantly increased in SBS biopsies, consistent with a role for this signaling pathway in human SBS. 
In our present observations of  adaptive intestine that has reached a “steady state” following resection, we 
observed an increase in WNT ligand and agonist expression (R-spondin 1, R-spondin 2, and WNT5a) without 
concomitant increased WNT signaling activity (Figure 4); in fact AXIN2 mRNA expression showed a trend 
to be decreased (P = 0.054), suggesting WNT signaling inhibition. These data suggest that the mesenchyme 
responds to the loss of  small bowel surface area by a compensatory increase in WNT and R-spondin ligand 
expression but that other counterregulatory mechanisms are activated to inhibit WNT signaling, possi-
bly to protect from chronic WNT stimulation that could result in tumor formation/carcinogenesis. BMP 
signaling is likely to be one of  these counterregulatory mechanisms (43). Our results do not exclude the 
possibility that WNT-driven expansion of  LGR5+ stem cells occurred at earlier times postresection, since 
our patients have had SBS for 6 months to more than 10 years.
The effect of  myofibroblasts on cocultured-enteroid growth suggests that examination of  other niche 
cell populations to elucidate effects on stem cell proliferation and expansion could provide novel therapeu-
tic targets for SBS. For example, FOXL1+ cells have been proposed to be critically important niche cells for 
maintaining a normal crypt; however, these cells are relatively rare, making isolation from human intestine 
challenging. The current findings point to an emerging role of  BMP signaling, but clearly other signals are 
yet to be identified in the adaptive response.
Methods
Human studies. All human studies were performed following protocols approved by the Washington Univer-
sity School of  Medicine’s Institutional Review Board, as per IRB 201504100. All studies were conducted 
according to Declaration of  Helsinki principles. Informed consent was obtained for all studies.
Patient population. Patients with SBS (n = 17; Table 1 and Supplemental Table 1) were recruited 
from the Gastroenterology Clinic at Washington University in St. Louis School of  Medicine or from 
Barnes-Jewish Hospital in St. Louis. SBS was defined as a residual small bowel length of  no more than 
200 cm, with or without part or all of  the colon in continuity. These included patients with jejunoileal 
anastomosis and ileostomy, jejunostomy, ileo-colonic anastomosis, or jejunocolonic anastomosis. As 
per standard practice, all patients were permitted to ingested oral enteral diets even if  receiving intra-
venous (parenteral) nutrition support.
Control subjects (n = 27) were recruited from the Center for Advanced Medicine Endoscopy Center 
at Washington University in St. Louis School of  Medicine/Barnes-Jewish Hospital or from the general 
surgical service. Endoscopy control patients included those who presented for routine colon cancer 
screening or for routine upper endoscopy for evaluation of  esophageal or gastric symptoms but were 
anticipated to have normal small intestine, which was confirmed during endoscopy. During colonosco-
py, the normal terminal ileum was intubated, and a biopsy was taken. Normal jejunum was obtained 
from patients undergoing intestinal fistula repair; biopsies were taken from normal adjacent mucosa 
from surgical intestinal specimens removed for fistula repair.
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Human intestinal enteroid isolation and passaging. Duodenal, ileal, and jejunal biopsy specimens were 
obtained from healthy patients during routine endoscopy for colon cancer screening, from upper endosco-
py for unrelated upper GI symptoms, or from adjacent normal small bowel obtained during fistula repair 
surgery as detailed above. SBS patient biopsies were obtained during routine clinically indicated endosco-
py or from surgical resections performed at Barnes-Jewish Hospital at the Washington University School 
of  Medicine in St. Louis. Patients ingested nothing by mouth for at least 6 hours prior to endoscopy and 
overnight prior to surgery. Small intestinal enteroids were isolated from biopsy samples as previously 
described (49). Biopsies were washed with Basic Crypt Media (BCM), consisting of  advanced DMEM/
F12 with HEPES 10 mM (MilliporeSigma D6421), supplemented with 100 U/mL penicillin/streptomy-
cin (MilliporeSigma), 2 mM Glutamax (Gibco, Thermo Fisher Scientific), and 10% FBS (Gibco, Thermo 
Fisher Scientific), then cut into small pieces and treated with collagenase type I (Invitrogen, Thermo 
Fisher Scientific, 17100-017) for 10 minutes at 37°C. Crypts were collected and resuspended in 10 mL 
BCM, filtered through a 70 μm strainer (MidSci), and centrifuged at 300g for 5 minutes. Enteroids were 
suspended in Matrigel (Corning, 3562237) and plated on 48-well plates. After allowing the crypt-Matrigel 
suspension to solidify for 10–15 minutes at 37°C, cultures were treated with CM produced from ATCC 
cell line L-WRN (CRL-3276), which contains Wnt3a (W), R-spondin (R), and Noggin (N), supplement-
ed with 10 μM Y-27632 (p160 ROCK inhibitor, MilliporeSigma, Y0503-1MG, dihydrochloride) and 10 
μM SB-431542 (TGF-β receptor antagonist, MilliporeSigma, SB-431542 hydrate). Culture medium was 
changed every 3 days. Enteroids were passaged to expand stem cells on day 7 after plating by gentle 
enzymatic digestion in 0.25% Trypsin/EDTA (Gibco, Thermo Fisher Scientific) for 5 minutes at 37°C, 
replated in Matrigel (50 crypts per 15 μL of  Matrigel) into a 48-well plate, and cultured in CM without the 
addition of  10 μM Y-27632. After up to 7 days in culture, stem cells were frozen for storage.
Stem cell enteroid initiation assays. Stem cells were thawed and cultured in Matrigel in CM supplemented with 
Y-27632 and SB 431542, grown for 7 days, and harvested from Matrigel by enzymatic digestion with 0.25% 
Trypsin/EDTA (Gibco, Thermo Fisher Scientific) and with pipetting up and down 20–40 times. Live cells were 
analyzed by staining with 0.4% trypan blue dye (Bio-Rad) and quantified by TC20 Automated Cell counter 
(Bio-Rad), then replated in Matrigel (50 cells per 15 μL of Matrigel) and grown in CM. Enteroids were imaged 
with a Zeiss Axiophot microscope with Apotome 2 attachment (Carl Zeiss Inc.) on days 3 and 7 after plating.
Stem cell initiation assays and quantitation of  enteroid growth. Stem cell–initiated enteroid numbers and size 
were quantified at 3 and 7 days after plating using Cytation 3 plate reader software (BioTek Gen 3.0). The 
images were analyzed to quantify total number of  viable enteroids per well. The total and average cross-sec-
tional area in the optical level of  focus was measured. Enteroid viability was defined by the presence of  
visually sharp borders along their basolateral (antiluminal) side.
Small bowel biopsies and ISEMF culture and isolation. ISEMFs were isolated from duodenal, jejunal, and 
ileal biopsies, obtained either from healthy patients during routine endoscopy for colon cancer screening 
or from adjacent normal small bowel obtained during fistula repair surgery and from SBS patients during 
routine clinically indicated endoscopy or from surgical resections performed at Barnes-Jewish Hospital at 
the Washington University School of  Medicine in St. Louis. Small intestinal biopsies were minced and 
incubated with 300 U/mL collagenase type I and 0.1 mg/mL dispase (Gibco, Thermo Fisher Scientific) 
for 2 hours at 37°C; washed with ISEMF culture medium (RPMI 1640 medium from Gibco, Thermo 
Fisher Scientific) supplemented with 10% FBS, antimycotic solution (Corning), and 10 μg/mL gentamicin 
(Gibco, Thermo Fisher Scientific); and plated in 6-well plates at 37°C. After ISEMFs attached and formed 
colonies, they were subsequently passaged, expanded, and plated in standard myofibroblast cell culture 
medium. This medium consisted of  DMEM/Glutamax (Invitrogen, Thermo Fisher Scientific) with 10% 
FBS (Invitrogen, Thermo Fisher Scientific) and penicillin/streptomycin (MilliporeSigma). The identity and 
purity of  isolated ISEMFs were determined by immunofluorescence to detect expression of  α-SMA and 
vimentin and confirm absence or weak positivity of  desmin expression (50). ISEMFs were imaged using a 
Zeiss Axiovert microscope with Apotome 2 optical sectioning apparatus (Carl Zeiss Inc.).
Enteroid-myofibroblast cocultures. ISEMFs from control or SBS patient biopsies were plated into 48-well 
plates at a density of  1 × 104 cells/cm2. Stem cells derived from crypts as above (see Human intestinal enteroid 
isolation and passaging) were frozen for storage and then thawed and cultured in Matrigel in CM supple-
mented with Y-27632 and SB 431542, grown for 3 days, and harvested from Matrigel by enzymatic diges-
tion with 0.25% Trypsin/EDTA (Gibco, Thermo Fisher Scientific) and with pipetting up and down 20–40 
times. Cells were replated in Matrigel (50 live cells per well) onto a 48-well plate, either directly into the well 
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as a monoculture or on top of  a preconfluent (~70%) monolayer of  ISEMFs cultured in CM (containing 
Wnt3a, R-spondin, noggin, Y-27632, and SB-431542).
Immunoblot analysis. Protein was extracted from phenol-ethanol phase after RNA and DNA precipita-
tion as outlined in the TRIzol (Invitrogen, Thermo Fisher Scientific) manufacturer’s manual. Briefly, an 
excess of  100% ethanol was added to the phenol-ethanol phase. Samples were vortexed and incubated for 
10 minutes at room temperature followed by centrifugation at 12,000g for 10 minutes at 4°C. Pellets were 
washed 2 times in 500 μL 95% ethanol and centrifuged at 7600g for 5 minutes at 4°C. After removing eth-
anol, pellets were air-dried for 5 minutes, and 40–100 μL of  TGH protein lysis buffer (Roche Life Science) 
containing 25 mM HEPES (pH 7.4), 10% glycerol, 1% Triton X-100, and 5 mM EDTA supplemented 
with complete protease inhibitor cocktail (Thermo Fisher Scientific) was added to samples. Samples were 
concentrated using the Protein- Concentrate (Micro) kit (catalog 2100, MilliporeSigma). Protein content 
was quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), and equal amounts of  
protein were loaded on NuPAGE 4%–12% polyacrylamide gradient gel (Life Technologies, Thermo Fisher 
Scientific) under reducing conditions and transferred to nitrocellulose membranes by iBLOT 2 dry blotting 
system (Life Technologies, Thermo Fisher Scientific). Membranes were blocked and probed with antibod-
ies directed against rabbit anti–p-Smad1/Smad5/Smad8 (Ser463/465) (1:200 MilliporeSigma, Ab3848-I). 
Mouse anti–β-actin (C4) (1:1000 Santa Cruz Biotechnology, A1713) was used as a loading control. The 
optical density of  the specific proteins was quantified by using LI-COR imaging system (Odyssey CLx 
infrared imaging system, LI-COR Biosciences).
Immunofluorescence analysis of  ISEMFs. ISEMFs were cultured on glass slides, fixed in formalin, and 
processed in situ for immunofluorescence analysis. Staining was performed to identify α-SMA (Abcam 
5694, rabbit antibody, 1:200), vimentin (Abcam 8978, mouse antibody, 1:50), and desmin (Abcam 15200, 
rabbit antibody, 1:50). Anti-rabbit FITC (catalog number 711-095-152), anti-mouse FITC (catalog number 
715-096-150), and anti-rabbit Cy3 (catalog number 111-165-144) was each used at 1:200 dilution (Jackson 
ImmunoResearch Laboratories). Nuclei were counterstained with VECTASHIELD with DAPI (VECTOR 
Laboratories). Cells were visualized using Nuance microscopy (Nuance Multispectral Imaging System).
Immunohistochemical analyses. Biopsies were fixed in formalin, dehydrated in 70% ethanol, and embedded 
in paraffin. Sections were cut (5 μm) and rehydrated. Heat-induced epitope retrieval (Reveal Decloaker 10x, 
Biocare Medical) was performed for 20 minutes, followed by 0.3% peroxidase ((HX0635-3 MilliporeSigma), 
and blocked in blocking buffer (MilliporeSigma) for 1 hour at room temperature. Specimens were incubated 
at 4°C overnight with mouse anti-Ki67 (1:400, ab156956, Abcam) or mouse anti-PDGFRα (16AI; 1:100, 
ab96569, Abcam), then washed, incubated for 30 minutes in a detection reagent (HRP-Polymer, Biocare 
Medical), and developed with DAB (Betazid DAB, Biocare Medical). Sections were counterstained with 
hematoxylin and visualized and photographed using an Olympus BX43 microscope (Olympus Life Science).
PDGFRα quantification. The number of  PDGFRα+ cells that were subjacent to the villi or to the crypts 
was quantified. To correct for differences in villus length and crypt depth, the number of  positive cells was 
counted in a rectangular box of  fixed area (230 μm × 165 μm), which was overlaid onto photomicrographs 
of  the villi, and crypts of  each biopsy were examined. Only intact villi and crypts on each histologic section 
were analyzed. *P = 0.031 by Student’s 2-tailed t test.
In situ hybridization analyses and quantitation. A target-specific oligonucleotide (ZZ) probe for Lgr5 was 
designed (Hs-LGR5-C3; 311021-C3; RNAscope, Advanced Cell Diagnostics, Bio-Techne). Multiplexed Flu-
orescent Reagent Kit v2-Hs (323135, Advanced Cell Diagnostics, Bio-Techne) was used as per the manu-
facturer’s protocol. Formalin-fixed, paraffin-embedded tissue blocks were sectioned at 4 μm, then mounted 
on slides (ColorView Adhesion Slides, StatLab). Slides were pretreated with sequential deparaffinization, 
hydrogen peroxide, target retrieval, and protease plus digestion, followed by Lgr5 probe hybridization, signal 
amplification, and detection. Probe hybridization was achieved by incubation of  mRNA target probes for 2 
hours at 40°C using a HybEZ oven (Advanced Cell Diagnostics, Bio-Techne). The signal was amplified by 
subsequent incubation of  Amp-1, Amp-2, Amp-3, HRP Signal and Opal Dye (Akoya Biosciences)/tyramide 
signal amplification, 2 drops each for 30, 30, 15, and 30 minutes, respectively, at 40°C using the HybEZ 
oven. Nucleic acids were stained using DAPI (Advanced Cell Diagnostics, Bio-Techne), and coverslips were 
mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific). The 3-plex negative control 
probe (Advanced Cell Diagnostics, Bio-Techne, 320871) was applied to separate histologic sections pro-
cessed in the same manner as those that received the Lgr5 probe. Slides were visualized under fluorescence 
microscopy (Zeiss Axiovert microscope with Apotome 2 optical sectioning apparatus by Carl Zeiss Inc.). 
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To analyze the number of  Hs-LGR5 molecules per cell in each SBS and normal small bowel biopsy, Lgr5+ 
signals were quantified in each positive cell using ImageJ.
qRT-PCR. RNA was isolated from small bowel biopsies using TRIzol (Invitrogen, Thermo Fisher 
Scientific) reagent according to the manufacturer’s instructions and extracted from ISEMFs using Nucle-
ospin RNA kit (Invitrogen, Thermo Fisher Scientific). Quantification of  RNA was performed using 
260/280 nm by NanoDrop 2000 (Thermo Fisher Scientific). Complementary DNA was generated from 1 
μg/μL of  RNA with SuperScript II RT cDNA synthesis kit (Invitrogen, Thermo Fisher Scientific), which 
was then amplified by PCR 2720 Thermal Cycler (Applied Biosystems, Thermo Fisher Scientific). Gene 
expression was determined by StepOnePlus system (Applied Biosystems, Thermo Fisher Scientific) using 
Fast SYBR Green Master Mix (Applied Biosystems, Thermo Fisher Scientific) for all PCRs. Primers used 
are listed in Table 2. Cycle threshold values were normalized to 18s mRNA levels. The fold induction was 
determined by the ΔΔCt method (51).
BMP4 effects on enteroids and enteroid-ISEMF cocultures. Stem cells were removed from frozen storage 
and incubated in enteroid CM with Wnt3a, R-spondin, SB-431542, and Y-27632, with or without noggin. 
Media were changed 3 days postplating. Imaging and quantitation of  surface area and cell count were per-
formed at 3 days postplating. ISEMF-enteroid cocultures were incubated in CM as above, with or without 
Table 2. PCR primer sequences






hFOXL1 (52) 5′-TTATTTGGCGGACAGTGACA-3′ 5′-ACACGGCATCAATCTTTTCC-3′
hPDGFRα 5′-GGAAGGTGGTTGAAGGAACA-3′ 5′-CCAGAGCAGAATGCCATAAGA-3′
hLGR5 5′-ACAAGGGAGACCTGGAGAATA-3′ 5′-GTGATGCTGGAGCTGGTAAA-3′
hEGFR 5′-GCTGGATGATAGACGCAGATAG-3′ 5′- TGGGAACGGACTGGTTTATG-3′
hCD44 5′-AAGACATCTAACCCAGCA-3′ 5′-GGTAGCAGGGATTCTGTC-3′
hCD34 5-ACACCTAGTACCCTTGGAAGT-3′ 5′-GCCTTGATGTCACTTAGGATAGG-3′






















hGLI3 5′-ACTACCACCCTCCTCATCTT-3′ 5′-CTGTGCAAGGAGCGGATATAG- -3′
hGLI1 5′-CTACATCAACTCCGGCCAATAG-3′ 5′-GGTTGGGAGGTAAGGATCAAAG-3′
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Bmp4 (25 ng/mL; recombinant human BMP4, 314-BP: R&D Systems, Bio-Techne), but without noggin. 
Cocultured enteroids were analyzed for size (surface area) and cell count at 3 days postplating.
Statistics. Data comparing mRNA expression and enteroid size and cell count from normal patient and 
SBS biopsies or from ISEMFs and enteroids were calculated as the mean ± SEM. Statistical significance 
was analyzed by 2-tailed Student’s t test (GraphPad, Prism 8) comparing normal with SBS samples. P val-
ues less than or equal to 0.05 were considered significant, and P values are reported in each figure legend.
Outlier values were determined using the rule that defines an outlier as a value larger than 1.5 times the 
interquartile range from the 75th percentile or smaller than 1.5 times the interquartile range from the 25th 
percentile. The subject with at least 1 outlier in the gene group was defined as an outlier. The association 
between outlier distribution and demographic variables was examined using 2-sample 2-tailed Student’s t 
test for continuous demographic variables and χ2 test for categorical demographic variables.
Study approval. All human studies reported in this manuscript were approved by the Institutional Review 
Board of  Washington University in St. Louis, as indicated in human studies protocol IRB 201504100. Writ-
ten informed consent was received from participants prior to inclusion in the study.
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